Biopharma AI
ByCan AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
How Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5 Years?
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
